The DAWN Antivirals Trial for Ambulatory COVID-19 Patients

Inclusion Criteria: * Aged 40 years or older; * At least 2 Covid-19 suggestive symptoms at the time of inclusion, with onset of a maximum of 5 days prior to enrolment, and which cannot be explained by an alternative cause, and defined by the current Sciensano case definition * Positive result on PCR test or rapid Ag test in the 7 days before inclusion or at the time of inclusion; * Patient is community dwelling; * Participant or their proxy is willing and able to give informed consent for participation in the trial; * Participant is willing to comply with all trial procedures. Exclusion Criteria: * Hospital admission is required at the time of possible recruitment; * Positive PCR or rapid antigen test for SARS-CoV-2 in the last 2 months other than a test at recruitment or in the 7 days prior to recruitment; * Participating in any other interventional drug clinical study before enrolment in the study; * Breastfeeding; * Known severe neurological disorder, especially seizures in the last 12 months; * Known allergy to camostat or molnupiravir; * Previous adverse reaction to, or currently taking, camostat or molnupiravir; * Patients in palliative care; * Pregnant women or women of childbearing potential who may become pregnant during the trial and don't agree to use any of the effective contraceptive measures lised above; * Judgement of the recruiting clinician deems participant ineligible.